Loading...
Market
Number of peer-reviewed studies confirming Zepbound's efficacy for sleep apnea by end of 2024?
3
Resolution / Starting Odds
No additional studies • 33%
1-2 additional studies • 33%
3 or more additional studies • 33%
Medical journals and research databases
Story
Eli Lilly's Zepbound Weight Loss Drug Shows Promise in Treating Sleep Apnea
Jun 22, 2024, 10:54 PM
A new study has found that a popular weight loss drug may also help treat sleep apnea, a condition where individuals struggle to breathe while sleeping. The drug, which is commonly used for obesity, showed potential in reducing the severity of sleep apnea. This discovery was highlighted at the American Diabetes Association's 84th Annual Scientific Sessions. The study's findings suggest that the drug could offer a dual benefit for patients dealing with both obesity and sleep apnea. Additionally, the drug's ability to improve blood pressure and other health measures was noted, further enhancing its therapeutic profile. Eli Lilly's Zepbound helped resolve obstructive sleep apnea in 43-51.5% of patients.
View original story
Similar markets
≥ 50% • 50%
< 50% • 50%
Less than 60% • 25%
60% to 70% • 25%
70% to 80% • 25%
More than 80% • 25%
Yes • 50%
No • 50%
Less than 100,000 • 25%
100,000 to 200,000 • 25%
200,001 to 300,000 • 25%
More than 300,000 • 25%
Novo Nordisk's Wegovy • 25%
Pfizer's Danuglipron • 25%
AstraZeneca's Roxadustat • 25%
Other • 25%
Approved without conditions • 33%
Approved with conditions • 33%
Not approved • 33%
≥ 40% • 25%
30-39% • 25%
20-29% • 25%
< 20% • 25%